山苦瓜萃物暨其區分物之腸泌素效應

Incretin Effects of Momordica charantia L.

黃婷妮(Ting-Ni Huang)

指導教授 ： 黃青真

國立臺灣大學/生命科學院/微生物與生化學研究所/碩士(2010年)

https://doi.org/10.6342/NTU.2010.02773

摘要

第二型糖尿病發生前乃會經過糖尿病前期，判定標準為禁食血糖與葡萄糖耐受性異常，因此如何於糖尿病前期有效地控制血糖，便成為避免發展成第二型糖尿病的重點之一。早期苦瓜為學界所知之降血糖成份，乃是透過皮下或是腹腔注射投予以達到功效之植物胰島素，然而亦有許多文獻指出，以口服的方式給予苦瓜可降低血糖。本實驗室過去研究顯示：口服山苦瓜之降血糖活性存在於水萃物、且會受熱破壞；攝取山苦瓜補充飲食之動物有較高之 insulinogenic index、以及肝臟 dpp4 (dipeptidyl peptidase 4) 基因表現較低之特徵。因此，本實驗假說為：苦瓜降血糖機制之一乃是透過「腸泌素效應」－ incretin effect。
細胞實驗中，建立腸道內分泌細胞株 STC-1 之 GLP-1 (glucagon-like peptide-1) 分泌量分析作為初步篩選苦瓜降血糖物質之平台，結果發現：山苦瓜水萃物刺激 GLP-1 分泌之倍數最高；有趣的是，苦瓜苦味粗萃物亦具有活化 GLP-1 分泌之潛力。進一步評估苦瓜於動物體透過 incretin effect 降低血糖之可能，選用以 30% 高奶油飲食誘發高血糖症狀之 C57BL/6J 公鼠，結果發現：單一劑量急性投予水萃物中、3 kD 以下小分子區分物可降低血糖，並且伴隨血液胰島素與 GLP-1 濃度增加；此功效受到 GLP-1 受器之拮抗物 Exendin-9 的抑制、但卻不影響血液 DPP4 活性。推測此萃物並非透過抑制 GLP-1 之降解、而是刺激腸道內分泌 L 細胞分泌 GLP-1，進而活化胰臟 beta 細胞分泌胰島素，與細胞實驗之結果吻合。此外，刺激 GLP-1 分泌活性成份中，可能有一些是苦瓜中的苦味化合物，活化了 L 細胞上的苦味受器以刺激 GLP-1 分泌。
本研究首次發現：苦瓜水萃物中 3 kD 以下小分子區分物，透過刺激 GLP-1 分泌、而活化胰臟 beta 細胞分泌胰島素之腸泌素效應，以達到降低血糖之功效。

關鍵字

腸泌素效應 ； GLP-1 ； 腸道內分泌 L 細胞 ； 苦瓜 ； 降血糖

並列摘要

The health impact of type 2 diabetes and impaired glucose homeostasis has become a significant public health concern. Bitter gourd (BG) has been used to treat diabetes in Indian traditional medicine. Early research has isolated an insulin-like peptide from BG and showed its hypoglycemic effect via intraperitoneal or subcutaneous administration. Nevertheless, recent studies demonstrated that orally administered BG also lowered blood glucose. Our previous feeding studies in C57BL/6J mice showed that the water extract (WE) of BG had best hypoglycemic activity which could be destroyed by heating. Based on the facts that bitter gourd diet had higher insulinogenic index during OGTT and lower dpp4 mRNA expression in liver, we hypothesized that one of the mechanisms for the hypoglycemic effect of bitter gourd was through incretin effect.
BG WE was separated by ultra-filtration which resulted in a small molecule (< 3kD, WES) and a large molecule (>3kD, WEL) fractions. WE and WES were further hydrolyzed by beta-glucosidase and sequentially extracted with ethyl acetate and butanol. These subfractions were evaluated for their incretin potential by measuring GLP-1 secretions of treated STC-1 cells, a murine enteroendocrine cell line. It was found that WE and most of all of its subfractions dose-dependently enhanced GLP-1 secretion. Interestingly, the crude extract of BG bitter tastants also had a GLP-1 inducing effect. To assess the incretin effect and glucose homeostasis of BG in vivo, C57BL/6J male mice were fed a high fat diet to induce hyperglycemia. A single dose administration of the WES to these mice significantly lowered plasma glucose which was associated with higher levels of plasma insulin and GLP-1. This hypoglycemic effect of WES was blocked by GLP-1 receptor antagonist, Exendin-9. No association of plasma DPP4 activity was observed.
These data suggested that the small MW active fraction of BG might contain (a) GLP-1 secretagogue(s) which may induce the secretion of GLP-1 in L cells. Higher circulating GLP-1 then activates GLP-1 receptor on pancreatic cells and stimulates insulin secretion. It appears that WE subfractions did not inhibit GLP-1 degradation. It is speculated that bitter tastants in BG might contribute, at least in part, to the enhanced GLP-1 secretion in enteroendocrine cells through the bitter taste receptors. This is the first study demonstrating an incretin effect of bitter gourd water extract.

並列關鍵字

incretin effect ； GLP-1 ； enteroendocrine L cell ； bitter gourd ； antihyperglycemia

參考文獻

行政院衛生署國民健康局 (2007). 修正我國代謝症候群之判定標準.

李天瑞 (2008). 數種食材萃物對脂肪或肌肉細胞葡萄糖攝取之影響. 國立台灣大學微生物與生化學研究所碩士論文.

許珊菁 (2006). 鼠模式中高脂飲食、肥胖與脂質調控基因之表現. 國立台灣大學微生物與生化學研究所博士論文.

Ahmed, I., Adeghate, E., Cummings, E., Sharma, A.K., and Singh, J. (2004). Beneficial effects and mechanism of action of Momordica charantia juice in the treatment of streptozotocin-induced diabetes mellitus in rat. Mol Cell Biochem 261, 63-70.

Alberti, K.G., Zimmet, P., and Shaw, J. (2006). Metabolic syndrome--a new world-wide definition. A Consensus Statement from the International Diabetes Federation. Diabet Med 23, 469-480.